Summary Healthcare sector has been a standout performer in 2020, a year marred by the coronavirus pandemic. ASX 300 healthcare company Integral Diagnostics’ FY20 NPAT up by 21.9%, and revenue rose by 18.7%. Integral Diagnostics completed...
Summary With a high prevalence that is expected to grow further, the obstructive sleep apnea (OSA) market is predicted to expand in the upcoming times. Sydney-headquartered SomnoMed Limited, engaged in developing devices for OSA treatment, repo...
The stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1.8 per cent higher on 21st August 2020 following the release of a significant update on PD1-Vaxx’s third ethics approval for Phase 1 trial. To...
Global health technology company, CardieX Limited (ASX:CDX) has experienced a stupendous price rally with a six-month investor return of more than 107% and three-month investor return of 145.45%, as on 20 August 2020. The increase can be attributed...
Summary Australian government intends to develop a national approach for digital health; however, challenges are hampering the pace of development. MedAdvisor reported a record revenue during Q4, up 41 per cent year-on-year, while FY20 reve...
Summary Healius reported FY20 results which were in line with the guidance provided. Underlying EBIT and underlying NPAT were A$102.7 million and A$55.4 million, respectively. Resilience in Healius’ Pathology division continued into July ...
Summary Marketer and distributor of healthcare products, EBOS Group, witnessed strong performances from both Healthcare and Animal Care segments in FY20; total revenue grew by 26.5%. With the distribution of healthcare products falling under es...
The share price of healthcare companies is on a watch as they announce impressive full-year results during the current reporting season. Many ASX 200 healthcare players have updated impressive FY20 results despite the challenging condition posed by...
Recently, Australia undertook strides to secure access to a promising vaccine in a move to diminish coronavirus pandemic and would offer free access to the vaccine for Australians. Scott Morrison Government has signed a landmark agreement with UK-...
Summary CSL Limited reported an NPAT of ~US$2,103 million for FY20, up 17% on a constant currency basis. The total full-year dividend rose to US$2.02 per share. CSL’s FY21 NPAT is expected to be in the range US$2,100-US$2,265 million at c...
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)
